Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Grant funding available through FDA’s Orphan Products Office. The latest on CDRH’s whistleblower email surveillance investigation. More regulatory news.

You may also be interested in...



Pressure Mounts On FDA After Public Release Of Surveillance Documents

Multiple investigations and lawsuits have opened in response to the matter, with more potentially to come. Some worry the intensifying issue has serious implications for the quality of the device center’s output.

Regulatory News In Brief

President Obama signs FDA user fee bill. FDA issues rules requiring PMAs for two pre-amendment devices. More regulatory news.

CDRH Spyware Suit: Whistleblowers Sue Agency Over Email Surveillance

Six current and former employees of FDA’s device center file suit in the U.S. District Court in Washington, D.C., arguing that email and computer surveillance violated their constitutional and legal whistleblower rights.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel